The question that redesigned cartilage surgery

The century-old answer Lee refused to repeat

'For a century we have answered worn cartilage in the same way,' Professor Paul Lee writes, 'and been surprised that the answer keeps arriving as metal.' That single sentence captures the starting point from which NanoACi grew — not a laboratory insight or a new material, but a question aimed at a pattern the field had largely stopped examining.

The pattern Lee identified ran like this: focal cartilage damage could, in the right circumstances, be addressed surgically — patched, drilled, or, through techniques such as Autologous Chondrocyte Implantation, biologically repaired. These were genuine advances. But for the larger group of patients who were too worn for a neat focal repair yet not ready to give up the joint they were born with, the profession's honest offer was, in Lee's words, to 'wait, and then we will replace it.' The destination — metal — was seldom in doubt; only the timing was managed.

Lee's quarrel was not with the science of cartilage repair, nor with the surgeons who developed it. His challenge was with the ceiling: that the field had inherited an endpoint and treated it as inevitable rather than asking whether a different question might produce a different answer. He invokes the logic — sometimes attributed to Einstein — that doing the same thing repeatedly while expecting different results is its own kind of problem. On his account, orthopaedics had not failed to solve cartilage; it had, for a long time, stopped asking whether metal was the only solution available.

That stopping point is where his response began — as a question, not yet an answer.

What it felt like to perform ACI from the inside

Performing ACI — not reading about it, not reviewing its outcomes, but actually doing it — is where the question sharpened into something Lee could no longer set aside. ACI is a validated technique: it remains part of the surgical offering at London Cartilage Clinic today, and its biological logic is sound. The issue Lee encountered was not the science. It was what the science cost the patient in system terms.

He describes that cost plainly: two hospital admissions, two anaesthetics, a weeks-long gap while harvested chondrocytes were grown in an external laboratory, then months of protected recovery once the implant was in place. 'A great deal of money,' he writes, 'and a great deal of a person's year — for one patch of cartilage.' That is what he means by the 'true price': not the surgical fee, but the total load placed on a person's life by the way the procedure was architecturally arranged.

It was the laboratory stage that the engineer in him kept returning to. Not because the cell culture was scientifically wrong — it was not — but because, when examined step by step, each element of the two-stage pathway existed for reasons that had accumulated historically rather than been derived from first principles. The harvest had to precede the implant. The implant required a second admission. The laboratory phase sat between them because external culture was the only available route to sufficient cell numbers at the time the technique was designed. Legacy, not logic, was holding the architecture in place.

That recognition — science intact, system unnecessarily burdened — is the hinge point. The discomfort it created was not doubt about ACI's value. It was the engineer's specific unease at a system carrying weight it no longer needed to carry.

Cartilage seen through an engineer's eyes

Two things shaped how Lee read cartilage: a surgical training that took him inside joints others only studied on imaging, and a PhD in Medical Engineering from Cardiff University that gave him a different vocabulary for the same territory. Engineers do not ask whether a system works. They ask which parts of it are necessary, and which have simply accumulated over time without anyone checking.

That second habit — the audit of necessity — is what Professor James Richardson helped direct. Richardson, whom Lee describes as 'a godfather of cartilage regeneration in the UK', was the mentor who turned Lee's technical restlessness toward the specific problem of cartilage repair. It was Richardson who taught him to think about the whole problem at once: not just the cell biology, not just the implant, but the entire procedural chain from harvest to recovery, and every step sitting between them.

What that lens revealed was a system whose science was sound but whose architecture had never been seriously questioned. The operative steps around cartilage repair had accumulated across decades; each made sense in its moment, and none had been formally reviewed since. That, for an engineer, is where the interesting work begins.

The founding question itself

The question Lee brought to cartilage surgery was not 'which operation produces the best outcome?' — a question the field had been investigating for decades — but something prior to that: does this need to be an operation at all?

That shift in frame changes what counts as progress. Rather than comparing techniques against one another, a necessity audit asks whether surgical access — the theatre, the arthroscopy, the anaesthetic — is the minimum form the intervention requires, or simply the form it has always taken. The distinction matters: one is a biological constraint, the other is inherited architecture.

Crucially, this is not a question about capability. Lee was not suggesting that surgery could not repair cartilage; ACI's clinical record was evidence enough that it could. The question was whether surgery was the only route that could — and, if not, what the smallest sufficient biological form of the intervention might look like.

That reframing opened a lane rather than closing one. Specialist judgement, biological intent, and rigorous case selection all remain: what becomes optional is the operative access around them. The question had a concrete answer.

NanoACi: the founding question encoded in a technique

NanoACi™ — Professor Paul Lee's surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique — is, in a precise sense, the founding question made procedural. Every word in the name is doing work: non-arthroscopic removes the keyhole; needle-delivered removes the theatre; one-stage removes the second admission and the external cell-culture laboratory that ACI requires between its two operations; autologous means nothing foreign enters the patient; chondrogenic specifies cartilage-generating biological intent, not mere cushioning.

The biological architecture follows the same logic. Three autologous components — cartilage micrografts as the seed, a cell-free type I collagen matrix as the scaffold, and platelet-rich fibrin as the signal — are sampled, prepared and delivered at point of care within one planned sitting. No cells leave for a laboratory. No enzyme digestion is involved in the preparation described. The procedure reaches the joint through a needle, but the clinical process surrounding it — imaging review, case selection, preparation, sequencing and follow-up — remains specialist work throughout.

That last point is what the manifesto holds in place: 'Keep the surgeon. Keep the science. Remove the arthroscopy.' Specialist judgement is the constant; surgical trauma and operational burden are the variables removed. Lee is explicit that the innovation is not removing the surgeon — it is removing surgical access that the founding question revealed to be no longer necessary. NanoACi sits as a constructive, non-arthroscopic lane for suitable patients, alongside rather than against the surgical discipline from which it grew.

From founding question to measured answer: NanoACi 100

Evidence for the three biological roles — cartilage micrografts, type I collagen scaffold, and platelet-rich fibrin — exists at component level independently of the combined protocol. NanoACi 100 is the step that brings those components together as a measured whole: a prospective outcomes programme designed to build a combined evidence base for the technique as it is actually delivered, in one planned sitting, by the surgeon who designed it.

The logic mirrors the founding question. Lee did not build a procedure and then search retrospectively for papers to justify it; he designed the evidence architecture to match the technique — one programme, one protocol, one outcomes set built prospectively from the outset. That engineering discipline, applied to measurement rather than just method, makes NanoACi 100 part of the same intellectual commitment as the procedure it studies.

Combined-protocol outcomes are in development. What already exists is a technique built from first principles, a transparent account of what was removed and why, and a programme constructed to record what follows. The question Lee posed — asked against a century of metal as the default answer — is now being answered in data, one patient at a time.